M Panella1, S Marchisio, M L Demarchi, L Manzoli, F Di Stanislao. 1. Department of Clinical and Experimental Medicine, Section of Public Health, Faculty of Medicine, University of Eastern Piedmont Amedeo Avogadro, 28100 Novara, Italy. mpanella@med.unipmn.it
Abstract
BACKGROUND: Hospital treatment of heart failure (HF) frequently does not follow published guidelines, potentially contributing to HF high morbidity, mortality and economic cost. The Experimental Prospective Study on the Effectiveness and Efficiency of the Implementation of Clinical Pathways was undertaken to determine how clinical pathways (CP) for hospital treatment of HF affected care variability, guidelines adherence, in-hospital mortality and outcomes at discharge. Methods/ DESIGN: Two-arm, cluster-randomised trial. Fourteen community hospitals were randomised either to the experimental arm (CP: appropriate therapeutic guidelines use, new organisation and procedures, patient education) or to the control arm (usual care). The main outcome was in-hospital mortality; secondary outcomes were length and appropriateness of the stay, rate of unscheduled readmissions, customer satisfaction, usage of diagnostic and therapeutic procedures during hospital stay and quality indicators at discharge. All outcomes were measured using validated instruments available in literature. RESULTS: In-hospital mortality was 5.6% in the experimental arm (n = 12); 15.4% in controls (n = 33, p = 0.001). In CP and usual care groups, the mean rates of unscheduled readmissions were 7.9% and 13.9%, respectively. Adjusting for age, smoking, New York Heart Association score, hypertension and source of referral, patients in the CP group, as compared to controls, had a significantly lower risk of in-hospital death (OR 0.18; 95% CI 0.07 to 0.46) and unscheduled readmissions (OR 0.42; 95% CI 0.20 to 0.87). No differences were found between CP and control with respect to the appropriateness of the stay, costs and patient's satisfaction. Except for electrocardiography, all recommended diagnostic procedures were used more in the CP group. Similarly, pharmaceuticals use was significantly greater in CP, with the exception of diuretics and anti-platelets agents. DISCUSSION: The introduction of a specifically tailored CP for the hospital treatment of HF was effective in reducing in-hospital mortality and unscheduled readmissions. This study adds to previous knowledge indicating that CP should be used to improve the quality of hospital treatment of HF. TRIAL REGISTRATION NUMBER: NCT00519038.
RCT Entities:
BACKGROUND: Hospital treatment of heart failure (HF) frequently does not follow published guidelines, potentially contributing to HF high morbidity, mortality and economic cost. The Experimental Prospective Study on the Effectiveness and Efficiency of the Implementation of Clinical Pathways was undertaken to determine how clinical pathways (CP) for hospital treatment of HF affected care variability, guidelines adherence, in-hospital mortality and outcomes at discharge. Methods/ DESIGN: Two-arm, cluster-randomised trial. Fourteen community hospitals were randomised either to the experimental arm (CP: appropriate therapeutic guidelines use, new organisation and procedures, patient education) or to the control arm (usual care). The main outcome was in-hospital mortality; secondary outcomes were length and appropriateness of the stay, rate of unscheduled readmissions, customer satisfaction, usage of diagnostic and therapeutic procedures during hospital stay and quality indicators at discharge. All outcomes were measured using validated instruments available in literature. RESULTS: In-hospital mortality was 5.6% in the experimental arm (n = 12); 15.4% in controls (n = 33, p = 0.001). In CP and usual care groups, the mean rates of unscheduled readmissions were 7.9% and 13.9%, respectively. Adjusting for age, smoking, New York Heart Association score, hypertension and source of referral, patients in the CP group, as compared to controls, had a significantly lower risk of in-hospital death (OR 0.18; 95% CI 0.07 to 0.46) and unscheduled readmissions (OR 0.42; 95% CI 0.20 to 0.87). No differences were found between CP and control with respect to the appropriateness of the stay, costs and patient's satisfaction. Except for electrocardiography, all recommended diagnostic procedures were used more in the CP group. Similarly, pharmaceuticals use was significantly greater in CP, with the exception of diuretics and anti-platelets agents. DISCUSSION: The introduction of a specifically tailored CP for the hospital treatment of HF was effective in reducing in-hospital mortality and unscheduled readmissions. This study adds to previous knowledge indicating that CP should be used to improve the quality of hospital treatment of HF. TRIAL REGISTRATION NUMBER: NCT00519038.
Authors: Anubha Agarwal; Ehete Bahiru; Sang Gune Kyle Yoo; Mark A Berendsen; Sivadasanpillai Harikrishnan; Adrian F Hernandez; Dorairaj Prabhakaran; Mark D Huffman Journal: Heart Date: 2019-01-30 Impact factor: 5.994
Authors: David A Cook; Kristi J Sorensen; Jane A Linderbaum; Laurie J Pencille; Deborah J Rhodes Journal: J Am Med Inform Assoc Date: 2017-07-01 Impact factor: 4.497
Authors: Massimiliano Panella; Sara Marchisio; Romeo Brambilla; Kris Vanhaecht; Francesco Di Stanislao Journal: BMC Med Date: 2012-07-10 Impact factor: 8.775
Authors: Kris Vanhaecht; Walter Sermeus; Jan Peers; Cathy Lodewijckx; Svin Deneckere; Fabrizio Leigheb; Steven Boonen; An Sermon; Paulo Boto; Rita Veloso Mendes; Massimiliano Panella Journal: BMC Health Serv Res Date: 2012-05-24 Impact factor: 2.655
Authors: Vera Maria Avaldi; Jacopo Lenzi; Ilaria Castaldini; Stefano Urbinati; Giuseppe Di Pasquale; Mara Morini; Adalgisa Protonotari; Aldo Pietro Maggioni; Maria Pia Fantini Journal: PLoS One Date: 2015-05-26 Impact factor: 3.240